Abstract |
We performed a randomized, double-blind trial on a relatively low-risk population comparing the use of three doses of cefoxitin vs. placebo in the prevention of infection following primary cesarean section. Major site-related morbidity ( endometritis, wound infection and septicemia) was significantly reduced in the cefoxitin group (8.9% vs. 27.8%; p = 0.017). Febrile morbidity alone tended to occur in the cefoxitin group (15.6% vs. 3.7%; p = 0.091), and all five urinary tract infections occurred in the cefoxitin group as well. Total morbidity was therefore not significantly different ( cefoxitin, 35.6%; placebo, 31.5% [not significant]). Duration of hospitalization (mean, 6.0 days) and need for further postoperative antibiotic therapy were similar in the two groups. Our study demonstrated a modest benefit from the perioperative use of antibiotics in relatively low-risk patients undergoing primary cesarean section. Issues that need further study include definition of the optimal prophylactic regimen and of high-risk populations for whom prophylaxis would be most helpful.
|
Authors | J L Tully, H Klapholz, L M Baldini, G H Friedland |
Journal | The Journal of reproductive medicine
(J Reprod Med)
Vol. 28
Issue 12
Pg. 827-32
(Dec 1983)
ISSN: 0024-7758 [Print] United States |
PMID | 6363696
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Cefoxitin
(therapeutic use)
- Cesarean Section
- Clinical Trials as Topic
- Double-Blind Method
- Endometritis
(epidemiology)
- Female
- Fever
(epidemiology)
- Humans
- Placebos
- Postoperative Complications
(epidemiology)
- Pregnancy
- Premedication
- Sepsis
(epidemiology)
- Surgical Wound Infection
(epidemiology)
- Urinary Tract Infections
(epidemiology)
|